Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy
NCT ID: NCT02669290
Last Updated: 2020-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
60 participants
INTERVENTIONAL
2007-01-31
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
3D Echocardiographic Assessment of Epicardial Pacing After Cardiopulmonary Bypass.
NCT02842762
Comparison of Cardiac Resynchronisation Therapy (CRT) Response Using High Frequency (HF) - ECG or Q-LV Guided Optimisation for Left Ventricular, Pacing Site.
NCT05829876
Surface ECG Mapping
NCT04221958
Utility of Analyzing Atrial Signal Electrograms in Patients with Atrial Fibrillation Using Next-Generation Ensite X Software: a Prospective Study
NCT06632925
Left Ventricular Myocardial Work for Predicting Response to CRT
NCT07319065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Delayed electrical activation of the LV translates to temporal delay in ventricular contraction. This is referred to as mechanical dyssynchrony. Patients with advanced HF, low ejection fraction (EF) of less than 35% and QRS of more than 120ms are indicated for cardiac resynchronization therapy (CRT). While most patients undergoing CRT implantation show dramatic improvement in HF symptoms, 30-40% of the HF patients undergoing CRT placement do not show a clinical response. The site of placement of the LV lead has been shown to be an important determinant of the effects of CRT.
Measurement of left ventricular ejection fraction (LVEF) is performed using non-invasive measures such as the MUGA. By using the available information on left ventricular systolic function the investigators plan on investigating the effects of MUGA-guided versus traditional LV lead placement for CRT.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Guided
Guided LV lead placement for CRT.
Guided
LV lead placement will be guided by left ventricular systolic function information from MUGA
Non-Guided
Non-guided LV lead placement for CRT.
Non-guided
LV lead placement will be conventional posterolateral placement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Guided
LV lead placement will be guided by left ventricular systolic function information from MUGA
Non-guided
LV lead placement will be conventional posterolateral placement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have an approved indication for CRT implantation
* Must have ischemic or nonischemic dilated cardiomyopathy
* Must have symptomatic HF with a New York Association (NYHA) Classification of III or IV
* Must be on optimal pharmacological therapy (this should include at the minimum, ACE inhibitor and beta-blocker therapy as tolerated.
* Must have left ventricular ejection fraction (LVEF) of ≤35%
* Must have ventricular conduction delay manifested as a QRS duration of \>120msec
* Must be able to provide informed consent for study participation and be willing to comply with follow-up tests and scheduled visits
Exclusion Criteria
* Physical limitations to ambulation
* Life expectancy of less than six months
* Pregnant or planning for pregnancy in the next 6 months (must have a negative pregnancy test 7 days prior to enrollment)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, San Francisco
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-04791
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.